Erratum to: Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial | Zendy

Thomas M. File | Zendy; Lisa Goldberg | Zendy; Anita Das | Zendy; Carolyn Sweeney | Zendy; John Saviski | Zendy; Steven P Gelone | Zendy; Elyse Seltzer | Zendy; Susanne Paukner | Zendy; Wolfgang W. Wicha | Zendy; George H. Talbot | Zendy; Leanne B. Gasink | Zendy

Open Access

Erratum to: Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial

Author(s) -

Thomas M. File,

Lisa Goldberg,

Anita Das,

Carolyn Sweeney,

John Saviski,

Steven P Gelone,

Elyse Seltzer,

Susanne Paukner,

Wolfgang W. Wicha,

George H. Talbot,

Leanne B. Gasink

Publication year - 2019

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciz710

Subject(s) - medicine , moxifloxacin , clinical endpoint , linezolid , bacterial pneumonia , placebo , pneumonia , population , confidence interval , community acquired pneumonia , randomized controlled trial , antibiotics , staphylococcus aureus , vancomycin , microbiology and biotechnology , genetics , alternative medicine , environmental health , pathology , bacteria , biology

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research